Highlights of ESC HF 2021 - Insights from the GALACTIC-HF Trial

Efficacy of Omecamtiv mecabril in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial. The primary outcome of this trial was the time to first heart failure event or cardiovascular death, which occurred significantly less in patients randomized to Omecamtiv mecabril group. In sub-analysis, the effect of Omecamtiv mecarbril on NT-pro BNP level, and pre-specified outcomes based on NT-pro BNP level i.e. < or > median value i.e. 1675 pg/ml, and on continuous NT-pro BNP level were also evaluated The result showed that Omecamtiv Mecarbril reduced NT-pro BNP levels more in patient with NT-pro BNP above-median than those with levels below the median The pre-specified outcome results showed that those with NT-pro BNP level above the median had higher event rates compared to those below the median. Those who were randomized to Omecamtiv Mecarbril had lower event rate compared to placebo, with higher risk reduction in those with NT-pro BNP level above the median, compared to those below median. If we look at continuous NT-pro BNP levels, the Omecamtiv Mecarbril arm had significant risk reduction at higher NT-pro BNP levels With this, the study concluded that baseline NT-pro BNP level modifies the treatment outcomes with Omecamtiv Mecarbril in HF patients without AF/F. The investigated drug greatly reduced NT-pro BNP level in those with above-median level of the marker, thus consistent to other analysis from Galactic-HF, this study suggests that Omecamtiv Mecabril has a greater benefit in patients with more severe Heart Failure with reduced ejection fraction. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.